Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mr. Quantumdot you can see I did my homework, the Canals go on "forever". So the weight of the Ships cannot disappear anywhere due to displacement !
Mr Quantumdot you are half correct but that is one very long bridge. It is All in the air, an Aqueduct they call it.
Stogi
Hello gofishmarko No it's very simple those floating ships weigh many tons or tonnes as they say over there. They are NEVER lighter just because they they seem to have a good relationship with the water. Optical illusion !!!
Ships plus Water and the OVERALL Weight is increasing all the time !!
I should know you can guess my profession afore I retired back home !
Kindest,
Stogi
Gotta correct you there Mr. Dew the presence of water does not make the weight of the ships any lighter !!!
You have fallen for the optical illushion of the big floating ship as in somehow it must be lighter weight. Wrong instead they equalize due to buoyancy displacement but the weight is still there.
Not at all. Every bit of the ships weights plus the massive weight of the water MUST be taken by the bridge columns and I bet they are heavily reinforced and very FAT !!
Regards Stogi
TARO ___ hey Mr. Genisi that "buyout" report from Israel looks like it may have been bait from a bunch of crooks. Stock has been de-listed and a VP is headed off along with half of his family to the crow-bar hotel for insider trading .
http://www.secinvestor.com/2006/12/11/Taro+In+Talks+With+Ofer+Fund.aspx
http://www.marketwatch.com/news/story/sec-charges-seven-insider-trading-scheme/story.aspx?guid=%7BCB...
Well I hope you or anyone on this board did not take the bait.
take care Stogi
Maybe many companies never reveal they are filing such appeals, you never hear of it then some-times they have a second chance mysteriously
Stogi
Ms Biowatch here's a little canadian that is using this very same FDA appeals process, good luck to them.
http://biz.yahoo.com/prnews/061220/to301.html?.v=8
Stogi
ps thank you for your nice note you sent me about chrissie hynde and her group, yes they had rhythm and nice lyrics in their heyday.
Deadb I dont see that the little Canadian is halted.
http://www.nasdaqtrader.com/asp/TradeHaltShowPage.asp
Were you smoking something cool just now, and your mind jes floated off with the possibles, like the morning fog with the sun comin up ....
Stogi
Sad to say Spartex can't eat anything here hotter than ketcjhup and chili i cant even look at without my eosophagus getting all queesy. But we'll have RPRX out of the $12-$13 box long before the offering is set cos the funds will want this stock. The over-under for me is the $13-$15 bracket - hows that for chili powder ?
Stogi
hello Spartex old friend you would like the RPRX action now it looks like we can bust $13 today.
maybe this new ipo can come off around $15 hey that would be nice
Hi Mr Dew thats not the unfortunate NUVO but instead its a little canadian I like called Nuvo Research symble NRI on the toronto exchange. THis is interesting news and maybe I will be buying.
Happy new year once again to yall from Ohio.
Stogi
blade you have a good golf name too you know, i dont think PGS will be offended if the spelling aint perfect this is just a message board, especially if he and Mr dew come up to god's country to play and I will show them my own due diligence they will be surprised.
you know a month ago i looked at the famous DNDN and moved on to something else, too much hair-splitting and crystal-ball staring with provenges NDA chances. But i wish you well if you own it.
happy new year and i will check in over the weekend.
Stogi
well Mr Dew i am in jack nicklaus home country and if ever Mr PGS or yourself are up here we have some nice courses nearby and I would be delighted to be hosting for 19 holes, 18 on the course and the last one being in the clubhouse on my tab and maybe we can talk biotech for 2007.
Stogi
Dr Bill just wanted to say that i aint sick of RPRX either and to thank you and all the docs here for your input, what a racehorse and still holding on here, not quitting.
Also will anyone be attending on the 4th in NYC and report back about the analyst day, i only get to those parts maybe twice a year. It would be apreciated.
Stogi
ok my friend i will check back over weekend, have a good one.
Stogi
poorgradstudent you know i saw an albino squirrel this morning and i said its going to lucky for someone today and i thought that maybe i should have both them Telik calls after all, even if the price made no sense.
so I checked on it and i see it crashed and burned like good old Dale Earnhart. May I extend my condolenses on a tough one and glad too see you had the putts too, that was a farseeing strategy.
Stogi
Alsan excuse me sir my delayed reply on ENMD.
For me its all about panzem and the other stuff is too early stage I know I will not be around holding it if and when they were to succeed.
Stogi
wonderbuy very interesting are you a maths geek ? and do you use maths when you consider a buy or do you prefer technicals ?
I have a suggestion too, its that your definitions should be posted up-front in the board header for all to see they are a very good summary.
Stogi
So these are the greeks or maybe they should be called the geeks. Do you figure them each time or no ?
Stogi
wonder_buy thnkx thats what I thought. Can I ask anotehr question, maybe its posted here already but year over year how well do you do with options ? I mean that when you hit a good one, then you have to give something back because of the 50c spreads. That doesnt happen with stocks any more since they tightened the rules once electronic trading came along.
Mr Wonderbuy you have a very nice website, may I ask a question seeing as the dozen otehr questions have all been answered by those links. Sorry am new to options. My dumb questin #1 is if the optionetics link for Basic Options is correct when it says that the strikes for under $25 stocks is at $2 intervals. I think they meant to say $2.50 intervals. My question #2 I think I know the answer to this but to be sure is an options contract a complete set of 100 options total, or rather an option on a 100 shares ?
I am willing to try Telik I remmber looking at it a year ago. Just got options approval on etrade (or should i write e*trade)and it may be my first ever buy of calls. I see the wise poorgradstudent is long so thats good enough for my DD especially with some play money. No foal No fee as we like to say. Maybe I will be the lucky one. Feel sorry for the northfield guys.
lots of luck with Telik ...... Stogi
Alsan sir do you really think ENMD could be a 10-bagger ? I have it and was going to dump it for a tax loss and buy something else especially since this financing. All the stock ever seems to do is financings usually after roadshows too to pump it up first. That panzy drug is like a pipe dream. Not that pipe dreams are all that bad but losing money is.
Stogi
In your PDF, those guys had HiV meaning AIDS ? Sorry I dont know this product. Is it on the market here.
Good times for RPRX longs a big thank you to the guys who introduced it here looks promising for next year. And seasons greetings too.
Stogi
amazing story about a hand transplant
look how long he had to wait too
Mich. Man Gets New Hand in Surgery
By BRETT BARROUQUERE
Associated Press Writer
LOUISVILLE, Ky. — A Michigan man who lost his right hand in a work-related accident more than 30 years ago became the third successful hand transplant recipient in the United States, doctors said Thursday.
David F. Savage was doing well the day after the surgery at Jewish Hospital in Louisville.
Doctors said the transplant for Savage, 54, presented unusual challenges because of the length of time between losing his hand in a machine press and the surgery. The blood vessels leading to Savage's hand had shrunk because they were not in use, said Dr. Warren Breidenbach, the lead surgeon.
"It's like closing down your house for 32 years, then deciding to go back in and take a shower. You turn it on, it sputters a little bit, then it works," Breidenbach said.
Of the two dozen hand transplant recipients worldwide, Savage may have gone the longest between losing a hand and having a transplant, Breidenbach said. That amount of time creates a "slightly higher risk" of vascular compromise, when blood stops flowing, because the blood vessels used in the transplant were dormant for so long, Breidenbach said.
"If it stops working, we'll go back in there and get it started again," Breidenbach said.
The procedure involved two surgeries and 32 doctors over 16 hours on Wednesday, the day the anonymous donor died.
Savage, of Bay City, Mich., is also serving as a test case for a drug called Campath to ward off rejection. If Savage's body rejects the new hand, it will happen in the first three to six months, doctors said.
Savage first inquired about receiving a hand transplant six years ago — shortly after the nation's first such procedure — and fought his insurance company for three years, Breidenbach said. Then he spent three years on a waiting list for a donor hand.
The first two U.S. hand transplants were also performed at Jewish Hospital, in 1999 and 2001.
Hi Randy Im not stogis but Stogi, like a stogie, for example a good one from havana.
I think the canadians are cheap and I might be buying this one soon even today. I followed it for a while reading all the posts here on it mostly by dr_bio who doesnt shoot any BS. I dont know the financials but I would guess they have to raise money because 3000 is a lot of patients. But all biotechs have to raise money so big deal.
Stogi
http://biz.yahoo.com/iw/061212/0193923.html
news from a little canadian liked and disliked on this board
Medicure Announces Special Protocol Assessment With the FDA For Phase III MEND-CABG II Study
Tuesday December 12, 7:32 am ET
WINNIPEG, MANITOBA--(MARKET WIRE)--Dec 12, 2006 -- Medicure Inc. (TSX:MPH.TO - News)(AMEX:MCU - News), a cardiovascular focused biopharmaceutical company, today announced that it has completed a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the Phase III MEND-CABG II study. This single confirmatory Phase III study for registration will evaluate the cardioprotective effects of the Company's FDA Fast Tracked product, MC-1, in approximately 3,000 patients undergoing coronary artery bypass graft (CABG) surgery. The SPA provides official confirmation from the FDA that the Phase III protocol is appropriately designed to form the basis of a New Drug Application (NDA) submission.
ADVERTISEMENT
"We are pleased to have finalized the SPA agreement with the FDA on the design of the ongoing MEND-CABG II trial. This agreement provides Medicure with a well defined pathway towards regulatory approval for MC-1," commented Medicure's President and CEO, Albert D. Friesen, PhD. "We believe MC-1 will be an important therapeutic addition to the standard of care for patients undergoing CABG surgery."
The SPA process creates a binding written agreement between the sponsoring company and the FDA concerning the design of pivotal clinical trials, including; clinical endpoints, study conduct, data analysis, and other clinical trial issues. The final approval of a product by the FDA requires demonstration of statistically significant efficacy and acceptable safety.
About MEND-CABG II
MEND-CABG II is a double-blind, randomized, placebo-controlled clinical trial that will enroll up to 3,000 patients undergoing CABG surgery at approximately 120 cardiac surgical centers throughout North America and Europe. Study patients will be randomized to receive placebo or MC-1 250 mg prior to surgery and for 30 days post operatively (POD 30). The primary efficacy endpoint of MEND-CABG II is the reduction in the composite of cardiovascular death and non-fatal myocardial infarction up to POD 30. Study patients will be followed for 60 days after treatment (90 days post operatively) for additional safety and efficacy analysis. Study enrollment was initiated in November 2006.
The study protocol and entry criteria for MEND-CABG II closely follow that of the Phase II MEND-CABG study. MEND-CABG was a Phase II study involving 901 patients that evaluated MC-1 versus placebo in patients undergoing CABG surgery. The 250 mg dose of MC-1 had a 37.2% reduction in the composite of cardiovascular death, non-fatal myocardial infarction (peak CK-MB greater than or equal to 100ng/ml), and non-fatal stroke versus placebo (p equals 0.028). The reduction in the composite endpoint was driven by a significant 46.9% decrease in the incidence of non-fatal myocardial infarction (peak CK-MB greater than or equal to 100ng/ml) with the 250 mg dose of MC-1 versus placebo (p equals 0.008). The clinical results reported at POD 30 were maintained throughout the 90 day follow up period (POD 90). Safety analysis included in the MEND-CABG study demonstrated MC-1 was safe and well tolerated. The incidence of adverse events in the study was comparable across both treatment and control groups.
Stogi
Analysts See More Drug Licensing Deals
Monday December 11, 12:30 pm ET
By Damian Troise, AP Business Writer
Analysts See More Drug Licensing Deals Amid Pipeline Holes
NEW YORK (AP) -- Last week's licensing deal between Roche Holding AG and Halozyme Therapeutics Inc. potentially worth as much as $581 million over the next 10 years marked another highlight for the biotechnology sector, as analysts predict licensing costs will get steeper.
ADVERTISEMENT
Licensing deals between pharmaceutical and biotechnology companies is the norm for the industry, giving development stage companies the money to continue developing products, while larger companies get a chance to bolster their product pipelines.
But with more large companies facing pipeline holes, biotech companies are seeing more money being thrown their way for innovative products, and the deals could lead to future acquisitions.
"That's going to continue to heat up and pick up," said Jason Napadano, senior biotechnology analyst at Zach's Investment Research. "The reason it's happening is that you have these large pharmaceutical companies with an unprecedented number of products going off patent."
That could amount to billions of dollars in losses for some of the major pharmaceutical companies.
The deal last week between Halozyme and Roche calls for the use of Halozyme's drug delivery technology in products being developed by Roche.
Some of the more standard licensing agreements entail the smaller biotechnology company developing the drug with payments from its larger partner, then splitting, in some form, the profits when it hits the market.
Bank of America analyst Eric Ende said in a November report that smaller biotech companies have been seeing higher deal prices as they seek to gain more control over their products. And big pharma has been willing to pay to fill lagging pipelines. The higher licensing prices are partially leading to more expensive buyout deals.
In October, Merck & Co. said it would buy small biotechnology outfit Sirna Therapeutics Inc. for $1.1 billion. Abbott Laboratories is in the process of buying Kos Pharmaceuticals for $3.7 billion.
"Big pharma could start knocking on the door of biotech with market caps of $5 billion," said Morningstar analyst Karen Andersen.
"If you're a pharmaceutical company and you want these products and need these products, biotech can continue to demand these types of big prices," Zack's Napadano said.
By most estimates, the market for licensing deals and pricier acquisitions will continue into 2007. News last week that Pfizer Inc. ended a late-stage program on its experimental heart drug highlighted the company's pipeline problems, with many analysts predicting it will acquire another company, possibly within the next year.
maybe he didnt like the new proposal, whatdya think ?
FDA
FOR IMMEDIATE RELEASE
P06-194
December 11, 2006
Media Inquiries:
Susan Cruzan, 301-827-6242
Consumer Inquiries:
888-INFO-FDA
FDA Proposes Rules Overhaul to Expand Availability of Experimental Drugs
The Agency Also Clarifies Permissible Charges to Patients
The Food and Drug Administration (FDA) today proposed significant regulatory changes to make experimental drugs more widely and easily available to seriously ill patients with no other treatment options and to clarify the circumstances and the costs for which a manufacturer can charge for an experimental drug.
Under the proposed rule, expanded access for experimental drugs would be available to individual patients, small patient groups, and larger populations under a treatment plan when there is no satisfactory alternative therapy to diagnose, monitor or treat the disease or condition.
"This proposed reform is carefully designed to balance several objectives," said Dr. Andrew C. von Eschenbach, Acting FDA Commissioner. "One goal is to enable many more patients who lack satisfactory alternatives to have access to unapproved medicines, while balancing the need for safeguarding the individual patient. Another equally important goal is to ensure the continued integrity of the scientific process that brings safe and effective drugs to the market."
"FDA hopes this proposal will increase awareness in the healthcare community of the range of options available for obtaining experimental drugs for seriously ill patients," added Dr. Janet Woodcock, FDA's Deputy Commissioner for Operations. "By clarifying and streamlining the processes, FDA also hopes to encourage companies to make such drugs available, and reduce barriers for healthcare practitioners in obtaining them."
FDA has allowed many types of access to experimental therapies since the 1970's. Some of the larger programs, including those under the treatment IND (Investigational New Drug) regulations, were successful in enabling tens of thousands of patients with HIV/AIDS, cancer and cardiovascular diseases to receive promising therapies before the products were approved for marketing. However, the existing regulations did not adequately describe the full range of programs available, explicitly recognizing only emergency use for individual patients and widespread treatment use access for large groups of patients. FDA believes it is important that its regulations clearly reflect the full range of treatment use programs available to ensure broad and equitable access to experimental drugs for treatment use. The regulations covering when it is appropriate to charge for an experimental drug need revisions because they fail to account for the full range of circumstances in which charging should be permissible and because they have proven difficult to interpret in practice, resulting in confusion over what costs could be recovered.
The proposed rules, which are open for comment for 90 days are described in detail at the following CDER web address: (http://www.fda.gov/cder/regulatory/applications/IND_PR.htm) The most significant proposals would:
(1) Modernize applicable regulations to include all circumstances under which access to experimental drugs is permitted, including:
* single patients in non-emergency and emergency settings;
* small groups of patients; and
* larger groups of patients under a treatment IND. To authorize these expanded access treatment uses, FDA generally must be satisfied that the patient's serious or immediately life-threatening disease or condition has no satisfactory approved therapy; that the potential benefit for the patient justifies the potential risks; and that providing the therapy will not interfere with the drug's development.
(2) Make experimental drugs more widely available in appropriate situations by establishing criteria that link the level of evidence needed to support the use of an experimental drug to the seriousness of the disease and the number of patients likely to be treated with the drug;
(3) Revise the current regulation regarding manufacturers' recovery of the costs of an experimental drug to:
* clarify that such charges are permissible in a clinical trial only to facilitate development of drugs that promise significant advantages over existing therapies, and might not otherwise be developed because of their high cost;
* clarify that allowing charging for treatment use of an experimental drug is intended to facilitate and encourage access to drugs that might not be made available for treatment use unless a manufacturer is able to recover its costs.
The proposal also would simplify the cost recovery calculation by making clear that charges for an experimental drug used in a clinical trial may include only direct costs associated with the drug's development, and that charges for experimental drugs for treatment use may also include administrative costs of making the drug available for intermediate
patient populations and under large scale treatment INDs.
Written comments, identified by Docket No. 2006N-0062 and RIN 0910-AF14 (for expanded access proposals) and Docket No. 2006N-0061 and/or RIN 0910-AF13, (for cost recovery proposals), may be submitted by any of the following methods:
* Federal eRulemaking Portal: http://www.regulations.gov. Follow the instructions for submitting comments.
* Agency Web site: http://www.fda.gov/dockets/ecomments. Follow the instructions for submitting comments on the agency Web site.
* FAX: 301-827-6870.
* Mail/Hand delivery/Courier [For paper, disk, or CD-ROM submissions]: Division of Dockets Management, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
OK but I know there has been talk that the patent restrations might be made longer, because it takes so much longer to get drugs approved today. Maybe thats in the bill? It would be good for biotech.
Stogi
MDCO's counsel should be fired anyway maybe the ceo too. Anyone know if the new bill would make patent extensions longer than 5 years? In europe its 10 years.
Stogi
thanks so maybe I will pitch $11 at it, seeing as you heard rumors and now we have the newspaper too.
Stogi
Your stock is only up a quarter, how reliable is that newspaper? Time to buy it?
Congrats Stogi
dont mention it but dont count your chickens yet, am on business and its hard to get aeround that city with all the xmas shoppers
Stogi
No wonder the jury was confused.
But enjoy the weekend I sure will, our rprx did good today
Stogi
Got it. Will try to make it there, get up close and personal.
Why not tonight ? Should say Thansk for detailed explanations you and dewophile have shown us all these past weeks.
Stogi
Excuse me again, but still dont understand the conversation, why talk about tercica accepting 30% royalties if insmed would never offer it ? Even now insmed could offer, but nobody thinks that will happen. Not even 20-25%.
Thanks Stogi
On a flight to NYC next week, might get to this show. Anyone have any questions to ask ? No guarentees I can put them or get answers.
Dead board here but DCGN is going to liven up once the tax sellers are done. Winter is the season that the Icelanders prefer.